Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 22, 2026CureusOpen Access

Clinical Safety Profile of Bruton’s Tyrosine Kinase (BTK) Inhibitors in Chronic Lymphocytic Leukaemia: A Real-World Ambispective Study From India

View Full Paper
Ask AI
Bookmark
Share

Authors

APArya PradhanHPHarsha Panchal

Discussion

Loading...

Member takes

Overview

Ambispective observational study evaluates safety of BTK inhibitors in CLL, highlighting improved outcomes.

Key Points

  • This study aims to evaluate the clinical safety profile of BTK inhibitors in patients with chronic lymphocytic leukaemia in India.
  • Single-centre ambispective observational study conducted from June 2021 to June 2024.
  • Included patients aged 18-70 diagnosed with chronic lymphocytic leukaemia.
  • Patients received either ibrutinib or acalabrutinib based on availability and physician's decision.
  • Among 93 patients, most were male and younger compared to typical Western cohorts.
  • High hematologic recovery rates with normalization of hemoglobin, platelets, and leukocytes within four to seven months.
  • Overall median progression-free survival was 14 months; acalabrutinib showed superior tolerability and adherence.

Cite This Study

Pradhan et al. (2026) studied this question.

synapsesocial.com/papers/6a0ff3ffd674f7c03778cfeehttps://doi.org/10.7759/cureus.109238
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy2025 · 122 citations
  2. 2<i>TP53</i> aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics2018 · 159 citations
  3. 3Chronic Lymphocytic Leukemia: Novel Therapeutic Targets Under Investigation2025 · 9 citations
  4. 4Chronic Lymphocytic Leukemia: Real-World Data From India2020 · 31 citations
  5. 5Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN2025 · 46 citations